BETA
New Jersey medical device developer building an implantable sub-scalp EEG platform for continuous brain monitoring, initially focused on epilepsy.
NeuroView Technology is an Englewood, New Jersey medical device company developing continuous brain-monitoring technology. Founded in 2017 by clinicians with backgrounds in epilepsy and neurosurgery, the company is led by CEO Scott Verner. Its initial focus is measuring seizure burden in people with epilepsy, particularly drug-resistant epilepsy.
Its NVT BVS, short for Brain Vital Sign, is a small implant designed to record electroencephalography, or EEG, from beneath the scalp and outside the skull. The platform combines the implant with data transmission, signal processing and clinician-guided analytics to provide a longitudinal record of brain activity between clinical visits.
NVT BVS remains investigational and is not available for sale. NeuroView is preparing for a pivotal clinical trial and an FDA De Novo submission. The company also identifies possible future applications in dementia, depression, movement disorders and other neurological conditions; these remain potential extensions rather than validated or approved uses.
NVT BVS is investigational and is not approved for sale in any jurisdiction. NeuroView says a completed pre-IDE meeting informed its planned FDA De Novo pathway and that it is preparing for a pivotal clinical trial. These are development and submission plans, rather than an existing marketing authorization. [3]
Published research compared subgaleal EEG with simultaneous intracranial recordings in 21 epilepsy patients monitored for up to 13 days. That study supports the sensing approach; it does not establish multi-year performance of the complete current implant. NeuroView separately reports an eight-week preclinical implant study in one beagle, with successful recording and no observed adverse effects. [1][4]
Latest recorded source review: 2026-11-04.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Investigational platform combining a sub-scalp EEG implant, data transmission and clinician-guided analysis to support long-term measurement of seizure burden. The implant is designed to sit beneath the scalp and outside the skull; it monitors brain activity rather than delivering neurostimulation. [7][3][1][4]
Investigational · Not available for saleCompany announced Verner’s appointment as it prepares for pivotal clinical development and a De Novo submission. [6]
Foundation announced a Shark Tank competition award to support NeuroView’s implantable EEG monitor. [9]
Company reported recording over eight weeks in one beagle, with removal as planned. [4]
Company announced support for development of continuous nervous-system monitoring technology. [5]
Company founded by clinicians working in epilepsy and neurosurgery. [10]
Accessed 11/04/2026
Last substantive review: 11/4/2026